{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:00:19Z","timestamp":1778536819818,"version":"3.51.4"},"reference-count":92,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1053\/j.seminoncol.2018.01.005","type":"journal-article","created":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T17:09:47Z","timestamp":1524416987000},"page":"404-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma"],"prefix":"10.1053","volume":"44","author":[{"given":"Hugo J.A.","family":"Adams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Kwee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2018.01.005_bib1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib4","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET-Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib6","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib7","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06077.x","article-title":"Fundamentals of PET and PET\/CT imaging","volume":"1228","author":"Basu","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"18)F-FDG avidity in lymphoma readdressed: a study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib10","first-page":"1838","article-title":"Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas","volume":"45","author":"Yamane","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00675.x","article-title":"Effect of drug-induced cytotoxicity on glucose uptake in Hodgkin's lymphoma cells","volume":"77","author":"Banning","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib12","first-page":"1972","article-title":"Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography","volume":"33","author":"Kubota","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/jcp.55.3.162","article-title":"Hodgkin's lymphoma: the pathologist's viewpoint","volume":"55","author":"Pileri","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1007\/s00259-010-1479-0","article-title":"Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET","volume":"37","author":"Brepoels","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2967\/jnumed.109.062208","article-title":"(18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model","volume":"50","author":"Brepoels","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib16","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis","volume":"85","author":"Adams","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.blre.2015.06.003","article-title":"Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma","volume":"29","author":"Adams","year":"2015","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib19","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib20","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2011.12.067","article-title":"Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging","volume":"84","author":"Dorth","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib22","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3109\/10428194.2011.585526","article-title":"Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma","volume":"52","author":"Marcheselli","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib23","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","author":"Phan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2013.02.007","article-title":"Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy","volume":"86","author":"Shi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13420","article-title":"Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis","volume":"170","author":"Adams","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-015-2529-2","article-title":"Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2015.63.7728","article-title":"Both interim and end-of-treatment 18F-fluoro-2-deoxy-d-glucose positron emission tomography scans have low value in diffuse large B-cell lymphoma","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-015-2553-2","article-title":"Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"issue":"Suppl 3","key":"10.1053\/j.seminoncol.2018.01.005_bib29","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib30","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib32","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.1200\/JCO.2005.02.907","article-title":"ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi","volume":"23","author":"Gobbi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib33","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","article-title":"Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi","volume":"29","author":"Chisesi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib34","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib36","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib37","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib38","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib39","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score \/= 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial","volume":"34","author":"Carde","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib40","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \/= 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib41","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib42","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib43","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2013.53.2838","article-title":"In vivo treatment sensitivity testing with positron emission tomography\/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma","volume":"32","author":"Hutchings","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","article-title":"Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients","volume":"39","author":"Zinzani","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib45","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib46","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2010.08485.x","article-title":"Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses","volume":"152","author":"Gallamini","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib47","first-page":"163","article-title":"Interim PET-adapted chemotherapy in advanced hodgkin lymphoma (HL). Results of the second interim analysis of the Italian gitil\/fil DH0607 trial","volume":"33","author":"Gallamini","year":"2015","journal-title":"Hematological Oncology"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib48","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdv077","article-title":"Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma","volume":"26","author":"Ganesan","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib49","first-page":"102","article-title":"Response-adapted therapy based on interim FDG-PET scans in advanced hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the International Rathl Study (cruk\/07\/033)","volume":"33","author":"Johnson","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib50","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib51","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 Study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMc1609333","article-title":"Interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"375","author":"Adams","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages hodgkin lymphoma: interim analysis of the AHL2011 lysa study","volume":"126","author":"Casasnovas","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib54","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/MNM.0000000000000418","article-title":"A negative 18F-FDG-PET scan can never exclude residual disease","volume":"37","author":"Adams","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib55","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib56","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000441962","article-title":"High-risk, advanced-stage Hodgkin lymphoma: the impact of combined escalated BEACOPP and ABVD treatment in patients who rapidly achieve metabolic complete remission on interim FDG-PET\/CT scan","volume":"135","author":"Kedmi","year":"2016","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib58","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/10428194.2011.603444","article-title":"Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone","volume":"53","author":"Markova","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib59","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/annonc\/mdp071","article-title":"Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy","volume":"20","author":"Sher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib60","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib61","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib62","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib63","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"Recher","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib64","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.critrevonc.2016.07.003","article-title":"Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis","volume":"106","author":"Adams","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib66","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Mamot","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib67","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/imj.12194","article-title":"Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings","volume":"43","author":"Chow","year":"2013","journal-title":"Intern Med J"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib68","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/MNM.0b013e328363c695","article-title":"Predictive value of interim (1)(8)F-FDG-PET\/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment","volume":"34","author":"Gonzalez-Barca","year":"2013","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib69","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","article-title":"Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Pregno","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib70","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00277-010-1135-6","article-title":"Limited role of interim PET\/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"90","author":"Yoo","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib71","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbmt.2008.11.026","article-title":"Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning","volume":"15","author":"Kasamon","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib72","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib73","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3109\/10428194.2013.862242","article-title":"Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma","volume":"55","author":"Stewart","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib74","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bjh.13036","article-title":"Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial","volume":"167","author":"Pardal","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjh.13389","article-title":"Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)","volume":"170","author":"Swinnen","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib76","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12149-014-0874-1","article-title":"The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma","volume":"28","author":"Lu","year":"2014","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib77","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428190701422059","article-title":"Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma","volume":"48","author":"Bishu","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib78","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib79","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s00259-017-3758-5","article-title":"Poor predictive value of positive interim FDG-PET\/CT in primary mediastinal large B-cell lymphoma","volume":"44","author":"Lazarovici","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib80","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2967\/jnumed.115.166769","article-title":"Prospective study of FLT PET for early interim response assessment in advanced stage B-cell lymphoma","volume":"57","author":"Schoder","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib81","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428194.2011.614704","article-title":"Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy","volume":"53","author":"Cox","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib83","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.23994","article-title":"The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the Fondazione Italiana Linfomi (FIL)","volume":"90","author":"Rigacci","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib84","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2015.04.021","article-title":"Interim PET after two ABVD cycles in early-stage Hodgkin lymphoma: outcomes following the continuation of chemotherapy plus radiotherapy","volume":"92","author":"Simontacchi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib85","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3109\/10428194.2012.735667","article-title":"Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy","volume":"54","author":"Filippi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib86","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/annonc\/mdq549","article-title":"End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib87","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5732\/cjc.014.10124","article-title":"Use of subsequent PET\/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy","volume":"34","author":"Zhang","year":"2015","journal-title":"Chin J Cancer"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib88","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-012-2320-8","article-title":"Interim FDG PET\/CT as a prognostic factor in diffuse large B-cell lymphoma","volume":"40","author":"Fuertes","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib89","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00277-012-1640-x","article-title":"Interim PET\/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era","volume":"92","author":"Yang","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib90","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.110.082586","article-title":"18F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation","volume":"52","author":"Cashen","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib91","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.01.005_bib92","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417301252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417301252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T04:06:56Z","timestamp":1604203616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775417301252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0093775417301252"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.01.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}